SCHEMBL9330773

SCHEMBL9330773

CCCCCCCC/C=C\CCCCCCCCN(CC)CCCCCCCC/C=C\CCCCCCCC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.52
TRPV1 Q8NER1 1/20 0.52
KCNH2 Q12809 4/20 0.47
EPHX2 P34913 1/20 0.46
TERT O14746 3/20 0.45
PTPN1 P18031 3/20 0.45
PPARG P37231 3/20 0.45
PPARD Q03181 3/20 0.45
PPARA Q07869 3/20 0.45
CYP1A2 P05177 2/20 0.45
MAPT P10636 2/20 0.45
CYP2C19 P33261 2/20 0.45
BLM P54132 2/20 0.45
HSD17B10 Q99714 2/20 0.45
FABP4 P15090 2/20 0.45
KMT2A Q03164 2/20 0.45
GMNN O75496 1/20 0.45
USP2 O75604 1/20 0.45
LMNA P02545 1/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21423390 1.00 FAAH (0.52) FAAHTRPV1KCNH2EPHX2TERT
SCHEMBL19032626 1.00 FAAH (0.52) FAAHTRPV1KCNH2EPHX2TERT
SCHEMBL11757316 1.00 FAAH (0.52) FAAHTRPV1KCNH2EPHX2TERT
SCHEMBL8853677 1.00 FAAH (0.52) FAAHTRPV1KCNH2EPHX2TERT
SCHEMBL8853696 1.00 FAAH (0.52) FAAHTRPV1KCNH2EPHX2TERT
SCHEMBL25498084 0.98 FAAH (0.50) FAAHTRPV1KCNH2EPHX2TERT
SCHEMBL5488036 0.95 FAAH (0.52) FAAHTRPV1KCNH2EPHX2TERT
SCHEMBL3272411 0.95 FAAH (0.52) FAAHTRPV1KCNH2EPHX2TERT
SCHEMBL3920135 0.95 FAAH (0.52) FAAHTRPV1KCNH2EPHX2TERT
Water SCHEMBL4537161 0.93 FAAH (0.50) FAAHTRPV1KCNH2EPHX2TERT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10881730-B2 Immunomodulatory therapeutic MRNA compositions encoding activating oncogene mutation peptides MODERNATX, INC. (US) 2021-01-05 US disclosed
US-20200131498-A1 POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE MODERNATX, INC. 2020-04-30 US disclosed
US-20190275170-A1 POLYNUCLEOTIDES ENCODING JAGGED1 FOR THE TREATMENT OF ALAGILLE SYNDROME MODERNATX, INC. (US) 2019-09-12 US disclosed
US-20190175727-A1 IMMUNOMODULATORY THERAPEUTIC MRNA COMPOSITIONS ENCODING ACTIVATING ONCOGENE MUTATION PEPTIDES ARES CAPITAL CORPORATION, AS AGENT 2019-06-13 US disclosed
US-5362910-A Germicidal and fungicidal agent and a germicidal and fungicidal method NICCA CHEMICAL CO., LTD. (JP) 1994-11-08 US disclosed
EP-0537426-A1 A germicidal and fungicidal agent and a germicidal and fungicidal method NICCA CHEMICAL CO., LTD. (JP) 1993-04-21 EP disclosed
US-4048118-A ALKALI METAL SALT OF ORGANIC ACID, AMINE SALT OF PHYTIC ACID SHOWA DENKO K.K. (JA) 1977-09-13 US disclosed
US-3956252-A BASIC NITROGEN-CONTAINING SALT OF PHYTIC ACID SHOWA DENKU K.K. (JA) 1976-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10881730-B2 Immunomodulatory therapeutic MRNA compositions encoding activating oncogene mutation peptides TP53, MYC, KRAS FAAH 4718/4885TRPV1 2754/4885KCNH2 4428/4885
US-20190175727-A1 IMMUNOMODULATORY THERAPEUTIC MRNA COMPOSITIONS ENCODING ACTIVATING ONCOGENE MUTATION PEPTIDES TP53, MYC, KRAS FAAH 4718/4885TRPV1 2754/4885KCNH2 4428/4885
US-20200131498-A1 POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE POLM, MCM6, MCM3 FAAH 3913/4885TRPV1 4873/4885KCNH2 4165/4885
US-20190275170-A1 POLYNUCLEOTIDES ENCODING JAGGED1 FOR THE TREATMENT OF ALAGILLE SYNDROME AARS1, IARS1, NOTCH1 FAAH 2004/4885TRPV1 3359/4885KCNH2 4296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.